Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 12 March, 2025
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo

ERIS Lifesciences Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 8, 2025, 8:02 pm

Market Cap 17,363 Cr.
Current Price 1,275
High / Low 1,594/809
Stock P/E52.7
Book Value 204
Dividend Yield0.58 %
ROCE11.3 %
ROE16.3 %
Face Value 1.00
PEG Ratio-34.10

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for ERIS Lifesciences Ltd

Competitors of ERIS Lifesciences Ltd

Stock Name ⇩Market Cap ⇩Current Price ⇩High / Low ⇩Stock P/E ⇩Book Value ⇩Dividend Yield ⇩ROCE ⇩ROE ⇩Face Value ⇩
MPS Pharmaa Ltd 6.71 Cr. 3.51 4.33/3.05 0.800.00 %9.15 %34.9 % 10.0
Gujarat Themis Biosyn Ltd 2,663 Cr. 244 390/19250.6 20.50.27 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 53.1 Cr. 71.5 94.9/32.118.0 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 38.0 Cr. 26.0 29.0/8.7438.8 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 70.4 Cr. 93.5 155/79.011.4 55.40.00 %14.4 %15.5 % 10.0
Industry Average17,255.37 Cr1,081.8442.42185.800.37%16.00%16.32%6.27

All Competitor Stocks of ERIS Lifesciences Ltd

Quarterly Result

MetricDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024
Sales 332306399461423403467505486551720741727
Expenses 210209269309286284297324311402470477477
Operating Profit 12297129151137119170181176148250265250
OPM % 37%32%32%33%32%30%36%36%36%27%35%36%34%
Other Income 58352113415254
Interest 11773917161833605957
Depreciation 17182329303541424654768081
Profit before tax 109851011211077611212611677115129116
Tax % 8%6%8%1%6%19%17%3%12%-4%22%25%25%
Net Profit 1018093119100619412210180899687
EPS in Rs 7.415.916.968.857.494.816.989.077.555.226.116.736.14

Last Updated: March 3, 2025, 4:35 pm

Below is a detailed analysis of the quarterly data for ERIS Lifesciences Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

  • For Sales, as of Dec 2024, the value is ₹727.00 Cr.. The value appears to be declining and may need further review. It has decreased from 741.00 Cr. (Sep 2024) to ₹727.00 Cr., marking a decrease of 14.00 Cr..
  • For Expenses, as of Dec 2024, the value is ₹477.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 477.00 Cr..
  • For Operating Profit, as of Dec 2024, the value is ₹250.00 Cr.. The value appears to be declining and may need further review. It has decreased from 265.00 Cr. (Sep 2024) to ₹250.00 Cr., marking a decrease of 15.00 Cr..
  • For OPM %, as of Dec 2024, the value is 34.00%. The value appears to be declining and may need further review. It has decreased from 36.00% (Sep 2024) to 34.00%, marking a decrease of 2.00%.
  • For Other Income, as of Dec 2024, the value is ₹4.00 Cr.. The value appears to be declining and may need further review. It has decreased from 5.00 Cr. (Sep 2024) to ₹4.00 Cr., marking a decrease of 1.00 Cr..
  • For Interest, as of Dec 2024, the value is ₹57.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 59.00 Cr. (Sep 2024) to ₹57.00 Cr., marking a decrease of 2.00 Cr..
  • For Depreciation, as of Dec 2024, the value is ₹81.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 80.00 Cr. (Sep 2024) to ₹81.00 Cr., marking an increase of ₹1.00 Cr..
  • For Profit before tax, as of Dec 2024, the value is ₹116.00 Cr.. The value appears to be declining and may need further review. It has decreased from 129.00 Cr. (Sep 2024) to ₹116.00 Cr., marking a decrease of 13.00 Cr..
  • For Tax %, as of Dec 2024, the value is 25.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 25.00%.
  • For Net Profit, as of Dec 2024, the value is ₹87.00 Cr.. The value appears to be declining and may need further review. It has decreased from 96.00 Cr. (Sep 2024) to ₹87.00 Cr., marking a decrease of 9.00 Cr..
  • For EPS in Rs, as of Dec 2024, the value is 6.14. The value appears to be declining and may need further review. It has decreased from ₹6.73 (Sep 2024) to 6.14, marking a decrease of ₹0.59.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 4:22 pm

MetricMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024TTM
Sales 3935095465977508569821,0741,2121,3471,6852,0092,739
Expenses 3074144274254805336377027818581,1461,3321,826
Operating Profit 8695118172269322345372431489539677913
OPM % 22%19%22%29%36%38%35%35%36%36%32%34%33%
Other Income 19732526311292292226
Interest 1000111232242685210
Depreciation 351620232636504365117183292
Profit before tax 8398109154270312317331394442405431437
Tax % 30%28%18%13%9%6%8%11%10%8%8%8%
Net Profit 587189135247295291297355406374397352
EPS in Rs 4,232.735,121.456,489.459,714.1817.9521.3921.1521.8426.1629.8828.1028.8224.20
Dividend Payout % 0%0%0%63%0%0%0%13%21%20%26%0%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-20232023-2024
YoY Net Profit Growth (%)22.41%25.35%51.69%82.96%19.43%-1.36%2.06%19.53%14.37%-7.88%6.15%
Change in YoY Net Profit Growth (%)0.00%2.94%26.33%31.28%-63.53%-20.79%3.42%17.47%-5.16%-22.25%14.03%

ERIS Lifesciences Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

No data available for the compounded sales growth chart.

Balance Sheet

Last Updated: January 13, 2025, 3:47 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital 0.140.140.140.14141414141414141414
Reserves 1061762662995538481,1371,2831,5631,8952,1822,5732,758
Borrowings 3110137717607848772,7812,735
Other Liabilities 639491981241701752052022333371,3751,516
Total Liabilities 1722713573976921,4081,5021,5021,7852,2263,4106,7427,022
Fixed Assets 277572712327717618758549182,5684,3285,295
CWIP 0000003422722207
Investments 478416719030336535678294520371679
Other Assets 981121191361572713835446367617832,3791,641
Total Assets 1722713573976921,4081,5021,5021,7852,2263,4106,7427,022

Below is a detailed analysis of the balance sheet data for ERIS Lifesciences Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

  • For Equity Capital, as of Sep 2024, the value is ₹14.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹14.00 Cr..
  • For Reserves, as of Sep 2024, the value is ₹2,758.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹2,573.00 Cr. (Mar 2024) to ₹2,758.00 Cr., marking an increase of 185.00 Cr..
  • For Borrowings, as of Sep 2024, the value is ₹2,735.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹2,781.00 Cr. (Mar 2024) to ₹2,735.00 Cr., marking a decrease of 46.00 Cr..
  • For Other Liabilities, as of Sep 2024, the value is ₹1,516.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹1,375.00 Cr. (Mar 2024) to ₹1,516.00 Cr., marking an increase of 141.00 Cr..
  • For Total Liabilities, as of Sep 2024, the value is ₹7,022.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹6,742.00 Cr. (Mar 2024) to ₹7,022.00 Cr., marking an increase of 280.00 Cr..
  • For Fixed Assets, as of Sep 2024, the value is ₹5,295.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹4,328.00 Cr. (Mar 2024) to ₹5,295.00 Cr., marking an increase of 967.00 Cr..
  • For CWIP, as of Sep 2024, the value is ₹7.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹20.00 Cr. (Mar 2024) to ₹7.00 Cr., marking a decrease of 13.00 Cr..
  • For Investments, as of Sep 2024, the value is ₹79.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹16.00 Cr. (Mar 2024) to ₹79.00 Cr., marking an increase of 63.00 Cr..
  • For Other Assets, as of Sep 2024, the value is ₹1,641.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹2,379.00 Cr. (Mar 2024) to ₹1,641.00 Cr., marking a decrease of 738.00 Cr..
  • For Total Assets, as of Sep 2024, the value is ₹7,022.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹6,742.00 Cr. (Mar 2024) to ₹7,022.00 Cr., marking an increase of 280.00 Cr..

Notably, the Reserves (₹2,758.00 Cr.) exceed the Borrowings (2,735.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +389090131200235223271375378292486
Cash from Investing Activity +-36-83-92-44-184-590-5123-323-320-975-1,828
Cash from Financing Activity +-3-20-84-24363-221-335-82-456881,380
Net Cash Flow-15-24-88-360-3014538

Free Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Free Cash Flow83.0094.00117.00172.00268.00-55.00169.00372.00424.00405.00-338.00675.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days151616162428315342446377
Inventory Days214166223178195178196148145166136182
Days Payable10913814292134247200213157166129258
Cash Conversion Cycle120439710284-4028-123044700
Working Capital Days31715923-13-175964769283
ROCE %98%64%47%53%60%34%26%25%27%25%17%11%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthSep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024
Promoters52.68%52.66%52.66%52.30%52.29%52.70%52.86%52.86%54.91%54.90%54.90%54.88%
FIIs13.60%13.34%13.31%15.35%15.39%15.50%14.86%13.78%13.20%13.13%14.27%14.59%
DIIs9.94%10.37%10.50%10.66%10.69%9.95%10.02%10.73%14.52%14.55%15.63%16.23%
Public23.78%23.62%23.52%21.69%21.63%21.85%22.27%22.63%17.37%17.41%15.20%14.30%
No. of Shareholders49,83354,22357,06151,63948,05546,74645,93144,16942,24546,49651,75344,176

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
HDFC Small Cap Fund - Regular Plan5,098,7131.89438.231,029,1262025-03-11395.44%
UTI Flexi Cap Fund2,573,0670.91221.161,029,1262025-03-11150.02%
Franklin India Smaller Companies Fund1,710,9001.52147.051,029,1262025-03-1166.25%
Aditya Birla Sun Life Equity Hybrid 95 Fund1,368,0301.7117.581,029,1262025-03-1132.93%
UTI Value Fund1,029,1261.1988.451,029,1262025-03-110%
HSBC Midcap Fund962,5801.0382.731,029,1262025-03-11-6.47%
HDFC Large and Mid Cap Fund - Regular Plan675,0000.4958.021,029,1262025-03-11-34.41%
UTI Mid Cap Fund591,6120.5850.851,029,1262025-03-11-42.51%
Tata ELSS Tax Saver Fund512,0001.2744.011,029,1262025-03-11-50.25%
UTI Dividend Yield Fund450,0001.2638.681,029,1262025-03-11-56.27%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue 1.001.001.001.001.00
Basic EPS (Rs.) 28.8228.1029.8926.1621.61
Diluted EPS (Rs.) 28.7928.0729.8826.1421.59
Cash EPS (Rs.) 42.6136.1234.6129.3225.54
Book Value[Excl.RevalReserv]/Share (Rs.) 190.11163.30140.35116.1095.47
Book Value[Incl.RevalReserv]/Share (Rs.) 190.11163.30140.35116.1095.47
Revenue From Operations / Share (Rs.) 147.70123.9299.1089.2579.10
PBDIT / Share (Rs.) 51.3640.2937.6032.3528.26
PBIT / Share (Rs.) 37.9431.6832.8429.1924.56
PBT / Share (Rs.) 31.7029.7632.5329.0524.40
Net Profit / Share (Rs.) 29.1927.5129.8526.1621.84
NP After MI And SOA / Share (Rs.) 28.8228.1029.8826.1621.84
PBDIT Margin (%) 34.7732.5137.9336.2435.73
PBIT Margin (%) 25.6825.5633.1332.7031.05
PBT Margin (%) 21.4624.0132.8232.5530.85
Net Profit Margin (%) 19.7622.2030.1229.3027.60
NP After MI And SOA Margin (%) 19.5022.6730.1429.3027.60
Return on Networth / Equity (%) 15.1517.4021.2822.5222.87
Return on Capital Employeed (%) 11.4213.3621.5323.7624.03
Return On Assets (%) 5.5610.4217.8719.3519.10
Long Term Debt / Equity (X) 0.250.290.020.000.00
Total Debt / Equity (X) 1.060.370.020.000.00
Asset Turnover Ratio (%) 0.370.520.610.670.67
Current Ratio (X) 0.901.733.142.802.91
Quick Ratio (X) 0.831.432.552.232.49
Inventory Turnover Ratio (X) 1.111.261.311.481.04
Dividend Payout Ratio (NP) (%) 0.0026.1520.1021.0213.14
Dividend Payout Ratio (CP) (%) 0.0020.0117.3418.7511.23
Earning Retention Ratio (%) 0.0073.8579.9078.9886.86
Cash Earning Retention Ratio (%) 0.0079.9982.6681.2588.77
Interest Coverage Ratio (X) 8.2420.94123.26243.78177.51
Interest Coverage Ratio (Post Tax) (X) 5.6815.3098.87198.08138.14
Enterprise Value (Cr.) 13413.398575.569359.518168.964936.17
EV / Net Operating Revenue (X) 6.685.096.956.744.60
EV / EBITDA (X) 19.2015.6518.3118.6012.86
MarketCap / Net Operating Revenue (X) 5.704.626.956.774.66
Retention Ratios (%) 0.0073.8479.8978.9786.85
Price / BV (X) 4.423.544.915.213.86
Price / Net Operating Revenue (X) 5.704.626.956.774.66
EarningsYield 0.030.040.040.040.05

After reviewing the key financial ratios for ERIS Lifesciences Ltd, here is a detailed analysis based on the latest available data and recent trends:

  • For FaceValue, as of Mar 24, the value is 1.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 1.00.
  • For Basic EPS (Rs.), as of Mar 24, the value is 28.82. This value is within the healthy range. It has increased from 28.10 (Mar 23) to 28.82, marking an increase of 0.72.
  • For Diluted EPS (Rs.), as of Mar 24, the value is 28.79. This value is within the healthy range. It has increased from 28.07 (Mar 23) to 28.79, marking an increase of 0.72.
  • For Cash EPS (Rs.), as of Mar 24, the value is 42.61. This value is within the healthy range. It has increased from 36.12 (Mar 23) to 42.61, marking an increase of 6.49.
  • For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 190.11. It has increased from 163.30 (Mar 23) to 190.11, marking an increase of 26.81.
  • For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 190.11. It has increased from 163.30 (Mar 23) to 190.11, marking an increase of 26.81.
  • For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 147.70. It has increased from 123.92 (Mar 23) to 147.70, marking an increase of 23.78.
  • For PBDIT / Share (Rs.), as of Mar 24, the value is 51.36. This value is within the healthy range. It has increased from 40.29 (Mar 23) to 51.36, marking an increase of 11.07.
  • For PBIT / Share (Rs.), as of Mar 24, the value is 37.94. This value is within the healthy range. It has increased from 31.68 (Mar 23) to 37.94, marking an increase of 6.26.
  • For PBT / Share (Rs.), as of Mar 24, the value is 31.70. This value is within the healthy range. It has increased from 29.76 (Mar 23) to 31.70, marking an increase of 1.94.
  • For Net Profit / Share (Rs.), as of Mar 24, the value is 29.19. This value is within the healthy range. It has increased from 27.51 (Mar 23) to 29.19, marking an increase of 1.68.
  • For NP After MI And SOA / Share (Rs.), as of Mar 24, the value is 28.82. This value is within the healthy range. It has increased from 28.10 (Mar 23) to 28.82, marking an increase of 0.72.
  • For PBDIT Margin (%), as of Mar 24, the value is 34.77. This value is within the healthy range. It has increased from 32.51 (Mar 23) to 34.77, marking an increase of 2.26.
  • For PBIT Margin (%), as of Mar 24, the value is 25.68. This value exceeds the healthy maximum of 20. It has increased from 25.56 (Mar 23) to 25.68, marking an increase of 0.12.
  • For PBT Margin (%), as of Mar 24, the value is 21.46. This value is within the healthy range. It has decreased from 24.01 (Mar 23) to 21.46, marking a decrease of 2.55.
  • For Net Profit Margin (%), as of Mar 24, the value is 19.76. This value exceeds the healthy maximum of 10. It has decreased from 22.20 (Mar 23) to 19.76, marking a decrease of 2.44.
  • For NP After MI And SOA Margin (%), as of Mar 24, the value is 19.50. This value is within the healthy range. It has decreased from 22.67 (Mar 23) to 19.50, marking a decrease of 3.17.
  • For Return on Networth / Equity (%), as of Mar 24, the value is 15.15. This value is within the healthy range. It has decreased from 17.40 (Mar 23) to 15.15, marking a decrease of 2.25.
  • For Return on Capital Employeed (%), as of Mar 24, the value is 11.42. This value is within the healthy range. It has decreased from 13.36 (Mar 23) to 11.42, marking a decrease of 1.94.
  • For Return On Assets (%), as of Mar 24, the value is 5.56. This value is within the healthy range. It has decreased from 10.42 (Mar 23) to 5.56, marking a decrease of 4.86.
  • For Long Term Debt / Equity (X), as of Mar 24, the value is 0.25. This value is within the healthy range. It has decreased from 0.29 (Mar 23) to 0.25, marking a decrease of 0.04.
  • For Total Debt / Equity (X), as of Mar 24, the value is 1.06. This value exceeds the healthy maximum of 1. It has increased from 0.37 (Mar 23) to 1.06, marking an increase of 0.69.
  • For Asset Turnover Ratio (%), as of Mar 24, the value is 0.37. It has decreased from 0.52 (Mar 23) to 0.37, marking a decrease of 0.15.
  • For Current Ratio (X), as of Mar 24, the value is 0.90. This value is below the healthy minimum of 1.5. It has decreased from 1.73 (Mar 23) to 0.90, marking a decrease of 0.83.
  • For Quick Ratio (X), as of Mar 24, the value is 0.83. This value is below the healthy minimum of 1. It has decreased from 1.43 (Mar 23) to 0.83, marking a decrease of 0.60.
  • For Inventory Turnover Ratio (X), as of Mar 24, the value is 1.11. This value is below the healthy minimum of 4. It has decreased from 1.26 (Mar 23) to 1.11, marking a decrease of 0.15.
  • For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 26.15 (Mar 23) to 0.00, marking a decrease of 26.15.
  • For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 20. It has decreased from 20.01 (Mar 23) to 0.00, marking a decrease of 20.01.
  • For Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 73.85 (Mar 23) to 0.00, marking a decrease of 73.85.
  • For Cash Earning Retention Ratio (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 40. It has decreased from 79.99 (Mar 23) to 0.00, marking a decrease of 79.99.
  • For Interest Coverage Ratio (X), as of Mar 24, the value is 8.24. This value is within the healthy range. It has decreased from 20.94 (Mar 23) to 8.24, marking a decrease of 12.70.
  • For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 5.68. This value is within the healthy range. It has decreased from 15.30 (Mar 23) to 5.68, marking a decrease of 9.62.
  • For Enterprise Value (Cr.), as of Mar 24, the value is 13,413.39. It has increased from 8,575.56 (Mar 23) to 13,413.39, marking an increase of 4,837.83.
  • For EV / Net Operating Revenue (X), as of Mar 24, the value is 6.68. This value exceeds the healthy maximum of 3. It has increased from 5.09 (Mar 23) to 6.68, marking an increase of 1.59.
  • For EV / EBITDA (X), as of Mar 24, the value is 19.20. This value exceeds the healthy maximum of 15. It has increased from 15.65 (Mar 23) to 19.20, marking an increase of 3.55.
  • For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 5.70. This value exceeds the healthy maximum of 3. It has increased from 4.62 (Mar 23) to 5.70, marking an increase of 1.08.
  • For Retention Ratios (%), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 30. It has decreased from 73.84 (Mar 23) to 0.00, marking a decrease of 73.84.
  • For Price / BV (X), as of Mar 24, the value is 4.42. This value exceeds the healthy maximum of 3. It has increased from 3.54 (Mar 23) to 4.42, marking an increase of 0.88.
  • For Price / Net Operating Revenue (X), as of Mar 24, the value is 5.70. This value exceeds the healthy maximum of 3. It has increased from 4.62 (Mar 23) to 5.70, marking an increase of 1.08.
  • For EarningsYield, as of Mar 24, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.04 (Mar 23) to 0.03, marking a decrease of 0.01.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of ERIS Lifesciences Ltd as of March 12, 2025 is: ₹1,410.04

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, ERIS Lifesciences Ltd is Undervalued by 10.59% compared to the current share price 1,275.00

Intrinsic Value of ERIS Lifesciences Ltd as of March 12, 2025 is: 1,388.25

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, ERIS Lifesciences Ltd is Undervalued by 8.88% compared to the current share price 1,275.00

Last 5 Year EPS CAGR: -1.55%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The stock has a high average ROCE of 40.58%, which is a positive sign.
  2. The company has higher reserves (1,203.00 cr) compared to borrowings (541.77 cr), indicating strong financial stability.
  3. The company has shown consistent growth in sales (357.00 cr) and profit (291.00 cr) over the years.
  1. The stock has a high average Working Capital Days of 35.75, which may not be favorable.
  2. The stock has a high average Cash Conversion Cycle of 47.17, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in ERIS Lifesciences Ltd:
    1. Net Profit Margin: 19.76%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 11.42% (Industry Average ROCE: 16%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 15.15% (Industry Average ROE: 16.32%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 5.68
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 0.83
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 52.7 (Industry average Stock P/E: 42.42)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 1.06
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Eris Lifesciences Ltd. is a Public Limited Listed company incorporated on 25/01/2007 and has its registered office in the State of Gujarat, India. Company's Corporate Identification Number(CIN) is L24232GJ2007PLC049867 and registration number is 049867. Currently Company is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company's Total Operating Revenue is Rs. 1486.71 Cr. and Equity Capital is Rs. 13.60 Cr. for the Year ended 31/03/2024.
INDUSTRYADDRESSCONTACT
PharmaceuticalsShivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Ahmedabad Gujarat 380054complianceofficer@erislifesciences.com
http://www.eris.co.in
Management
NamePosition Held
Mr. Amit BakshiChairperson & Managing Director
Mr. Krishnakumar VaidyanathanCOO & Executive Director
Mr. Inderjeet Singh NegiExecutive Director
Mr. Kaushal ShahExecutive Director
Mr. Rajeev DalalIndependent Director
Mr. Sujesh VasudevanIndependent Director
Ms. Kalpana UnadkatIndependent Director
Mr. Prashant GuptaIndependent Director

FAQ

What is the latest intrinsic value of ERIS Lifesciences Ltd?

The latest intrinsic value of ERIS Lifesciences Ltd as on 12 March 2025 is ₹1410.04, which is 10.59% higher than the current market price of 1,275.00, indicating the stock is undervalued by 10.59%. The intrinsic value of ERIS Lifesciences Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹17,363 Cr. and recorded a high/low of ₹1,594/809 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹2,758 Cr and total liabilities of ₹7,022 Cr.

What is the Market Cap of ERIS Lifesciences Ltd?

The Market Cap of ERIS Lifesciences Ltd is 17,363 Cr..

What is the current Stock Price of ERIS Lifesciences Ltd as on 12 March 2025?

The current stock price of ERIS Lifesciences Ltd as on 12 March 2025 is ₹1,275.

What is the High / Low of ERIS Lifesciences Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of ERIS Lifesciences Ltd stocks is ₹1,594/809.

What is the Stock P/E of ERIS Lifesciences Ltd?

The Stock P/E of ERIS Lifesciences Ltd is 52.7.

What is the Book Value of ERIS Lifesciences Ltd?

The Book Value of ERIS Lifesciences Ltd is 204.

What is the Dividend Yield of ERIS Lifesciences Ltd?

The Dividend Yield of ERIS Lifesciences Ltd is 0.58 %.

What is the ROCE of ERIS Lifesciences Ltd?

The ROCE of ERIS Lifesciences Ltd is 11.3 %.

What is the ROE of ERIS Lifesciences Ltd?

The ROE of ERIS Lifesciences Ltd is 16.3 %.

What is the Face Value of ERIS Lifesciences Ltd?

The Face Value of ERIS Lifesciences Ltd is 1.00.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in ERIS Lifesciences Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE